COPD and Asthma Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) and by Geography (North America, Europe, Asia-Pacific, LAMEA) - Global Opportunity Analysis and Industry Forecasts, 2014-2022

CHAPTER 1 INTRODUCTION

1.1 Report description

1.2 Key benefits

1.3 Key market segments

1.4 Reseaarch methodology

1.4.1 Secondary research

1.4.2 Primary research

1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope

3.2 Key findings

3.2.1 Top investment pockets

3.2.2 Top winning strategies

3.3 Porters five forces analysis

3.3.1 Bargaining power of buyers (High)

3.3.2 Bargaining power of suppliers (Low to Moderate)

3.3.3 Threat of new entrants (Low)

3.3.4 Threat of substitutes (High)

3.3.5 Intense competitive rivalry

3.4 Market dynamics

3.4.1 Drivers

3.4.1.1 Increasi in number of asthmatic and COPD patients worldwide

3.4.1.2 Increase in world ageing population

3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs

3.4.1.4 Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD

3.4.1.5 Increasing number of products in the pipeline

3.4.2 Restraints

3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs

3.4.2.2 Asthma and COPD drugs show side effects

3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming

3.4.2.4 Patent expiry of asthma and COPD drugs

3.4.3 Opportunities

3.4.3.1 Inrtoduction of generic drugs of asthma and COPD drugs

3.5 Market share analysis, 2015

CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE

4.1 Overview

4.2 Asthma

4.2.1 Global prevalence

4.2.2 Key growth factors and opportunities

4.2.3 Market size and forecast

4.3 COPD

4.3.1 Global prevalence

4.3.2 Key growth factors and opportunities

4.3.3 Market size and forecast

CHAPTER 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS

5.1 Overview

5.2 Combination Drugs

5.2.1 Market size and forecast

5.2.2 Seretide/Advair

5.2.3 Symbicort

5.2.4 Relvar/Breo Ellipta

5.2.5 Flutiform

5.2.6 Dulera

5.3 Leukotriene antagonists (LTA)

5.3.1 Market size and forecast

5.3.2 Singulair

5.4 Inhaled corticosteroids (ICS)

5.4.1 Market size and forecast

5.4.2 Qvar

5.4.3 Pulmicort

5.4.4 Aerospan

5.4.5 Flovent

5.5 Anticholinergics

5.5.1 Market size and forecast

5.5.2 Spiriva

5.6 Short acting beta agonists (SABA)

5.6.1 Market size and forecast

5.6.2 ProAir

5.6.3 Ventolin

5.7 Long acting beta agonists (LABA)

5.7.1 Market size and forecast

5.8 Others

5.8.1 Market size and forecast

CHAPTER 6 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key market trends

6.2.2 Key growth factors and opportunities

6.2.3 Market size and forecast

6.2.4 U.S.: market size and forecast

6.2.5 Canada market size and forecast

6.2.6 Mexico: market size and forecast

6.3 Europe

6.3.1 Key market trends

6.3.2 Key growth factors and opportunities

6.3.3 Germany: market size and forecast

6.3.4 France market size and forecast

6.3.5 UK: market size and forecast

6.3.6 Italy market size and forecast

6.3.7 Rest of Europe: market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends

6.4.2 Key growth factors and opportunities

6.4.3 Market size and forecast

6.4.4 Japan: market size and forecast

6.4.5 China market size and forecast

6.4.6 India: market size and forecast

6.4.7 Rest of Asia-Pacific market size and forecast

6.5 LAMEA

6.5.1 Key market trends

6.5.2 Key growth factors and opportunities

6.5.3 Market size and forecast

6.5.4 Latin America: market size and forecast

6.5.5 Middle East market size and forecast

6.5.6 Africa: market size and forecast

CHAPTER 7 GLOBALASTHMA AND COPD DRUGS PIPELINE -2015

CHAPTER 8 COMPANY PROFILES

8.1 Boehringer Ingelheim International GmbH

8.1.1 Company overview

8.1.2 Operating business segments

8.1.3 Business performance

8.1.4 Key strategic moves & developments

8.2 Merck & Co., Inc.

8.2.1 Company overview

8.2.2 Operating business segments

8.2.3 Business performance

8.2.4 Key strategic moves & developments

8.3 GlaxoSmithKline PLC.

8.3.1 Company overview

8.3.2 Operating business segments

8.3.3 Business performance

8.3.4 Key strategic moves & developments

8.4 Novartis AG

8.4.1 Company overview

8.4.2 Operating business segments

8.4.3 Business performance

8.4.4 Key strategic moves & developments

8.5 AstraZeneca

8.5.1 Company overview

8.5.2 Operating business segments

8.5.3 Business performance

8.5.4 Key strategic moves & developments

8.6 F. Hoffmann-La Roche Ltd

8.6.1 Company overview

8.6.2 Operating business segments

8.6.3 Business performance

8.6.4 Key strategic moves & developments

8.7 Teva Pharmaceutical Industries Ltd.

8.7.1 Company overview

8.7.2 Operating business segments

8.7.3 Business performance

8.7.4 Key strategic moves & developments

8.8 Vectura Group plc.

8.8.1 Company overview

8.8.2 Operating business segments

8.8.3 Business performance

8.8.4 Key strategic moves & developments

8.9 Pfizer, Inc.

8.9.1 Company overview

8.9.2 Operating business segments

8.9.3 Business performance

8.9.4 Key strategic moves & developments

8.10 Abbott Laboratories

8.10.1 Company overview

8.10.2 Operating business segments

8.10.3 Business performance

8.10.4 Key strategic moves & developments

List of Figures

FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET

FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016

FIG. 3 PORTERS FIVE FORCES ANALYSIS OF GLOBALASTHMA AND COPD DRUGS MARKET

FIG. 4 TOP IMPACTING FACTORS: GLOBALASTHMA AND COPD DRUGS MARKET

FIG. 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2015 & 2022 (% SHARE)

FIG. 6 GLOBALASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 7 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)

FIG. 8 COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 9 COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)

FIG. 10 SERETIDE/ADVAIT MARKET, 2014-2022 ($MILLION)

FIG. 11 SYMBICORT MARKET, 2014-2022 ($MILLION)

FIG. 12 RELVAR/BREO ELLIPTA MARKET, 2014-2022 ($MILLION)

FIG. 13 FLUTIFORM MARKET, 2014-2022 ($MILLION)

FIG. 14 FLUTIFORM MARKET, 2014-2022 ($MILLION)

FIG. 15 SINGULAIR MARKET, 2014-2022 ($MILLION)

FIG. 16 QVAR MARKET, 2014-2022 ($MILLION)

FIG. 17 PULMICORT MARKET, 2014-2022 ($MILLION)

FIG. 18 AEROSPAN MARKET, 2014-2022 ($MILLION)

FIG. 19 FLOVENT MARKET, 2014-2022 ($MILLION)

FIG. 20 SPIRIVA MARKET, 2014-2022 ($MILLION)

FIG. 21 PROAIR MARKET, 2014-2022 ($MILLION)

FIG. 22 PROAIR MARKET, 2014-2022 ($MILLION)

FIG. 23 U.S.: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 24 CANADA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 25 MEXICO: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 26 GERMANY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 27 FRANCE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 28 UK: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 29 ITALY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 30 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 31 JAPAN: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 32 CHINA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 33 INDIA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 34 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 35 LATIN AMERICA: ASTHMA AND COPD DRUGSMARKET, 2014-2022 ($MILLION)

FIG. 36 MIDDLE EAST: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 37 AFRICA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)

FIG. 38 BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)

FIG. 39 BOEHRINGER INGELHEIM: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 40 BOEHRINGER INGELHEIM: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 41 MERCK: REVENUE, 2013-2015 ($MILLION)

FIG. 42 MERCK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 43 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 44 GSK: REVENUE, 2013-2015 ($MILLION)

FIG. 45 GSK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 46 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 47 NOVARTIS: REVENUE, 2013-2015 ($MILLION)

FIG. 48 NOVARTIS: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 49 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 50 ASTRAZENECA: REVENUE, 2013-2015 ($MILLION)

FIG. 51 ASTRAZENECA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 52 ASTRAZENECA: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 53 ROCHE: REVENUE, 2013-2015 ($MILLION)

FIG. 54 ROCHE: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 55 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 56 TEVA: REVENUE, 2013-2015 ($MILLION)

FIG. 57 TEVA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 58 TEVA: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 59 VECTURA: REVENUE, 2013-2015 ($MILLION)

FIG. 60 PFIZER: REVENUE, 2013-2015 ($MILLION)

FIG. 61 PFIZER: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 62 PFIZER: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 63 ABBOTT: REVENUE, 2013-2015 ($MILLION)

FIG. 64 ABBOTT: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)

FIG. 65 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)

List of Tables

TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)

TABLE 2 ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 3 COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 4 ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS TYPE, 2014-2022 ($MILLION)

TABLE 5 COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 6 LTA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 7 ICS DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 8 ANTICHOLINERGICS DRUG MARKET, BY GEOGRAPHY,

TABLE 9 2014-2022 ($MILLION)

TABLE 10 SABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 11 LABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 12 OTHER DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 13 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)

TABLE 14 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 15 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)

TABLE 16 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)

TABLE 17 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 18 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)

TABLE 19 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)

TABLE 20 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 21 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)

TABLE 22 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)

TABLE 23 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 24 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)

TABLE 25 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)

TABLE 26 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT

TABLE 27 BOEHRINGER INGELHEIM: OPERATING SEGMENTS

TABLE 28 MERCK: COMPANY SNAPSHOT

TABLE 29 MERCK: OPERATING SEGMENTS

TABLE 30 GSK: COMPANY SNAPSHOT

TABLE 31 GSK: OPERATING SEGMENTS

TABLE 32 NOVARTIS: COMPANY SNAPSHOT

TABLE 33 NOVARTIS: OPERATING SEGMENTS

TABLE 34 ASTRAZENECA: COMPANY SNAPSHOT

TABLE 35 ASTRAZENECA: OPERATING SEGMENT

TABLE 36 ROCHE: COMPANY SNAPSHOT

TABLE 37 ROCHE: OPERATING SEGMENTS

TABLE 38 TEVA: COMPANY SNAPSHOT

TABLE 39 TEVA: OPERATING SEGMENTS

TABLE 40 VECTURA: COMPANY SNAPSHOT

TABLE 41 VECTURA: OPERATING SEGMENTS

TABLE 42 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT

TABLE 43 PFIZER: OPERATING SEGMENTS

TABLE 44 ABBOTT: COMPANY SNAPSHOT

TABLE 45 ABBOTT: OPERATING SEGMENTS